金属核素在放射免疫治疗药物中的应用  

Application of Metal Nuclides in Treatment Drugs of Radioimmunotherapy

作　　者：张君丽[1,2] 李洪玉[1,2] 

机构地区：[1]原子高科股份有限公司,北京102413 [2]中国原子能科学研究院同位素研究所,北京102413

出　　处：《同位素》2015年第2期113-120,共8页Journal of Isotopes

摘　　要：恶性肿瘤及其转移瘤的放射免疫靶向治疗越来越受到重视,已经成为治疗核医学的重要发展方向之一。放射免疫治疗药物对肿瘤细胞具有靶向选择性杀伤作用,可减少对正常非靶组织的损伤。鉴于131I标记单抗易在体内脱碘,近年来,金属核素在单抗药物方面的应用已成为放射免疫治疗药物的研究重点。本文分别从金属核素、双功能螯合剂和放射免疫靶向治疗药物三个方面对金属核素标记放射免疫治疗药物的发展现状进行了综述。Targeted radioimmunotherapy of malignant tumors and their metastases have been paid more and more attention ,and have become a major exploration area of thera‐peutic nuclear medicine .The radiopharmaceuticals for radioimmunotherapy can serve as targeted carriers of radionuclides to malignant tumors ,meanw hile decrease the damage to non‐targeted normal tissues .Due to the in‐vivo deiodination of 131 I labelled mono‐clonal antibodies （MoAbs） ,the application of metal radionuclides plays a more impor‐tant role in the development of radiolabelled MoAbs .The current status of the develop‐ment of metal radionuclides labelled MoAbs for radioimmunotherapy in three aspects ：metal radionuclides ,bifunctional chelating agents and radiopharmaceuticals for radioim‐munotherapy were summarized .

关 键 词：放射性金属核素 单克隆抗体 放射性免疫治疗 

分 类 号：TL923[核科学技术—核燃料循环与材料]